

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
8.0	17.06.2025	10808158-00009	Date of first issue: 05.07.2022

---

**Section 1: Identification**

Product name : Levamisole / Oxfendazole Formulation

Other means of identification : Scanda (A007130)

**Manufacturer or supplier's details**

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908  
Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON) 0800 243 622 (0800  
CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

**Section 2: Hazard identification****GHS Classification**

Respiratory sensitisation : Category 1

Skin sensitisation : Category 1

Reproductive toxicity : Category 1

Specific target organ toxicity - : Category 2 (Liver, Testis)  
repeated exposure

Specific target organ toxicity - : Category 2 (Blood, Testis)  
repeated exposure (Oral)

Hazardous to the aquatic : Category 1  
environment - acute hazard

Hazardous to the aquatic : Category 2  
environment - chronic hazard

**GHS label elements**

## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
8.0	17.06.2025	10808158-00009	14.04.2025
			Date of first issue: 05.07.2022

Hazard pictograms



Signal word

: Danger

Hazard statements

: H317 May cause an allergic skin reaction.  
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.  
H360FD May damage fertility. May damage the unborn child.  
H373 May cause damage to organs (Liver, Testis) through prolonged or repeated exposure.  
H373 May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swallowed.  
H400 Very toxic to aquatic life.  
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements

: **Prevention:**  
P201 Obtain special instructions before use.  
P260 Do not breathe mist or vapours.  
P272 Contaminated work clothing should not be allowed out of the workplace.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.  
P284 Wear respiratory protection.

**Response:**  
P302 + P352 IF ON SKIN: Wash with plenty of water.  
P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.  
P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.  
P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.  
P391 Collect spillage.

**Storage:**  
P405 Store locked up.

**Disposal:**  
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

## Section 3: Composition/information on ingredients

## Levamisole / Oxfendazole Formulation

Version 8.0      Revision Date: 17.06.2025      SDS Number: 10808158-00009      Date of last issue: 14.04.2025  
 Date of first issue: 05.07.2022

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
levamisole hydrochloride	16595-80-5	$\geq 2.5$ -< 10
oxfendazole	53716-50-0	$\geq 2.5$ -< 10
Polyethylene glycol stearate	9004-99-3	$\geq 1$ -< 10
Citric acid	77-92-9	$\geq 1$ -< 10
Sodium metabisulphite	7681-57-4	$\geq 0.1$ -< 1

**Section 4: First-aid measures**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
 Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
 Remove contaminated clothing and shoes.  
 Get medical attention.  
 Wash clothing before reuse.  
 Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.  
 Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
 Get medical attention.  
 Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May cause an allergic skin reaction.  
 May cause allergy or asthma symptoms or breathing difficulties if inhaled.  
 May damage fertility. May damage the unborn child.  
 May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

**Section 5: Fire-fighting measures**

Suitable extinguishing media : Water spray  
 Alcohol-resistant foam  
 Carbon dioxide (CO<sub>2</sub>)  
 Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
8.0	17.06.2025	10808158-00009	Date of first issue: 05.07.2022

---

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Hazchem Code : 3Z

---

**Section 6: Accidental release measures**

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

**Section 7: Handling and storage**

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.

---

## Levamisole / Oxfendazole Formulation

Version 8.0      Revision Date: 17.06.2025      SDS Number: 10808158-00009      Date of last issue: 14.04.2025  
 Date of first issue: 05.07.2022

- Do not breathe mist or vapours.  
 Do not swallow.  
 Avoid contact with eyes.  
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
 Keep container tightly closed.  
 Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
 When using do not eat, drink or smoke.  
 Wash contaminated clothing before re-use.  
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.  
 Store locked up.  
 Keep tightly closed.  
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents

## Section 8: Exposure controls/personal protection

## Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
levamisole hydrochloride	16595-80-5	TWA	20 µg/m <sup>3</sup> (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	200 µg/100 cm <sup>2</sup>	Internal
oxfendazole	53716-50-0	TWA	40 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	400 µg/100 cm <sup>2</sup>	Internal
Polyethylene glycol stearate	9004-99-3	WES-TWA	10 mg/m <sup>3</sup>	NZ OEL
		TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH
Sodium metabisulphite	7681-57-4	WES-TWA	5 mg/m <sup>3</sup>	NZ OEL
	Further information: Skin sensitiser, Respiratory sensitiser			
		TWA	5 mg/m <sup>3</sup>	ACGIH

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
8.0	17.06.2025	10808158-00009	Date of first issue: 05.07.2022

---

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

**Personal protective equipment**

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Particulates type

**Hand protection**

**Material** : Chemical-resistant gloves

**Remarks** : Consider double gloving.

**Eye protection** : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

---

**Section 9: Physical and chemical properties**

Appearance	: Aqueous solution
Colour	: No data available
Odour	: No data available
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
8.0	17.06.2025	10808158-00009	Date of first issue: 05.07.2022

---

Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	Not applicable

---

**Section 10: Stability and reactivity**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
8.0	17.06.2025	10808158-00009	Date of first issue: 05.07.2022

---

Incompatible materials : Oxidizing agents  
Hazardous decomposition products : No hazardous decomposition products are known.

---

**Section 11: Toxicological information**

Exposure routes : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

**Components:****levamisole hydrochloride:**

Acute oral toxicity : LD50 (Rat): 180 mg/kg  
LD50 (Mouse): 223 mg/kg  
LD50 (Rabbit): 458 mg/kg  
Acute inhalation toxicity : Remarks: No data available  
Acute dermal toxicity : Remarks: No data available

**oxfendazole:**

Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg  
LD50 (Dog): 1,600 mg/kg  
LD50 (sheep): 250 mg/kg

**Polyethylene glycol stearate:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

**Citric acid:**

Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg  
Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity

**Sodium metabisulphite:**



**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
8.0	17.06.2025	10808158-00009	Date of first issue: 05.07.2022

---

Acute oral toxicity : LD50 (Rat): 1,540 mg/kg  
Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat): > 5.5 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Remarks: Based on data from similar materials

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****levamisole hydrochloride:**

Remarks : No data available

**oxfendazole:**

Species : Rabbit  
Result : No skin irritation

**Polyethylene glycol stearate:**

Species : Rabbit  
Method : Draize Test  
Result : No skin irritation

**Citric acid:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

**Sodium metabisulphite:**

Result : Skin irritation  
Remarks : Based on national or regional regulation.

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****levamisole hydrochloride:**

Remarks : No data available

**oxfendazole:**

Species : Rabbit

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
8.0	17.06.2025	10808158-00009	Date of first issue: 05.07.2022

---

Result : No eye irritation

**Polyethylene glycol stearate:**

Species : Rabbit  
Result : No eye irritation  
Method : Draize Test

**Citric acid:**

Species : Rabbit  
Result : Irritation to eyes, reversing within 21 days  
Method : OECD Test Guideline 405

**Sodium metabisulphite:**

Species : Rabbit  
Result : Irreversible effects on the eye  
Method : OECD Test Guideline 405

**Respiratory or skin sensitisation****Skin sensitisation**

May cause an allergic skin reaction.

**Respiratory sensitisation**

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Components:****levamisole hydrochloride:**

Remarks : No data available

**Polyethylene glycol stearate:**

Test Type : Open epicutaneous test  
Exposure routes : Skin contact  
Species : Guinea pig  
Result : negative

**Sodium metabisulphite:**

Assessment : Probability or evidence of skin sensitisation in humans  
Remarks : Based on national or regional regulation.

Assessment : May cause sensitisation by inhalation.  
Remarks : Based on national or regional regulation.

**Chronic toxicity****Germ cell mutagenicity**

Not classified based on available information.

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
8.0	17.06.2025	10808158-00009	Date of first issue: 05.07.2022

---

**Components:****levamisole hydrochloride:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

**oxfendazole:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow  
cytogenetic test, chromosomal analysis)  
Species: Mouse  
Application Route: Oral  
Result: positive

**Polyethylene glycol stearate:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

**Citric acid:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: in vitro micronucleus test  
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow  
cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Sodium metabisulphite:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Method: OECD Test Guideline 476  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo  
cytogenetic assay)

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
8.0	17.06.2025	10808158-00009	Date of first issue: 05.07.2022

---

Species: Mouse  
Application Route: Subcutaneous  
Method: OECD Test Guideline 474  
Result: negative  
Remarks: Based on data from similar materials

**Carcinogenicity**

Not classified based on available information.

**Components:****levamisole hydrochloride:**

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
NOAEL : 80 mg/kg body weight  
Remarks : No significant adverse effects were reported

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
NOAEL : 40 mg/kg body weight  
Remarks : No significant adverse effects were reported

**oxfendazole:**

Species : Rat  
Application Route : Oral  
Exposure time : 1 Years  
Symptoms : No adverse effects  
Target Organs : Liver

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
Symptoms : No adverse effects  
Target Organs : Liver

**Sodium metabisulphite:**

Species : Mouse  
Application Route : Ingestion  
Exposure time : 24 Months  
Result : negative  
Remarks : Based on data from similar materials

**Reproductive toxicity**

May damage fertility. May damage the unborn child.

**Components:****levamisole hydrochloride:**

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
8.0	17.06.2025	10808158-00009	Date of first issue: 05.07.2022

---

Effects on fertility : Test Type: Three-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
Result: No significant adverse effects were reported

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 20 mg/kg body weight  
Result: Fetotoxicity

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: LOAEL: 40 mg/kg body weight  
Result: Fetotoxicity

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

**oxfendazole:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male  
Application Route: Oral  
Fertility: NOAEL: 17 mg/kg body weight  
Target Organs: Testes  
Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 0.9 mg/kg body weight  
Target Organs: Liver  
Result: No effects on fertility

Test Type: Fertility  
Species: Mouse  
Application Route: Oral  
Duration of Single Treatment: 1 Months  
Fertility: NOAEL: 750 mg/kg body weight  
Target Organs: Testes  
Result: Effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 10 mg/kg body weight  
Result: positive, Fetal effects

Test Type: Embryo-foetal development  
Species: Rat  
Developmental Toxicity: NOAEL: 10 mg/kg body weight

## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
8.0	17.06.2025	10808158-00009	Date of first issue: 05.07.2022

---

Result: positive, Embryo-foetal toxicity

Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: NOAEL: 108 mg/kg body weight  
Result: positive, Embryo-foetal toxicity, foetal abnormalities

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 0.625 mg/kg body weight

Reproductive toxicity - Assessment : Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

**Citric acid:**

Effects on foetal development : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Sodium metabisulphite:**

Effects on fertility : Test Type: Three-generation study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Ingestion  
Result: negative

**STOT - single exposure**

Not classified based on available information.

**Components:****Citric acid:**

Assessment : May cause respiratory irritation.

**STOT - repeated exposure**

May cause damage to organs (Liver, Testis) through prolonged or repeated exposure.  
May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swallowed.

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
8.0	17.06.2025	10808158-00009	Date of first issue: 05.07.2022

---

**Components:****levamisole hydrochloride:**

Target Organs	:	Blood, Testis
Assessment	:	May cause damage to organs through prolonged or repeated exposure.

**oxfendazole:**

Exposure routes	:	Oral
Target Organs	:	Liver, Testis
Assessment	:	May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****levamisole hydrochloride:**

Species	:	Rat
NOAEL	:	2.5 mg/kg
Application Route	:	Oral
Exposure time	:	18 Months
Target Organs	:	Testis

Species	:	Dog
LOAEL	:	20 mg/kg
Application Route	:	Oral
Exposure time	:	18 Months
Target Organs	:	Blood

Species	:	Dog
LOAEL	:	40 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months

**oxfendazole:**

Species	:	Rat
NOAEL	:	11 mg/kg
Application Route	:	Oral
Exposure time	:	2 Weeks
Target Organs	:	Blood, Liver, Testis

Species	:	Rat
NOAEL	:	3.8 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Liver, Testis

Species	:	Mouse
NOAEL	:	750 mg/kg
Application Route	:	Oral

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
8.0	17.06.2025	10808158-00009	Date of first issue: 05.07.2022

---

Exposure time : 1 Months  
Target Organs : Liver

Species : Mouse  
NOAEL : 37.5 mg/kg  
Application Route : Oral  
Exposure time : 3 Months  
Target Organs : Liver

Species : Dog  
NOAEL : 6 mg/kg  
Application Route : Oral  
Exposure time : 1 Months  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 11 mg/kg  
Application Route : Oral  
Exposure time : 2 Weeks  
Target Organs : Lymph nodes, thymus gland

Species : Dog  
NOAEL : 13.5 mg/kg  
Application Route : Oral  
Exposure time : 12 Months  
Target Organs : Liver

**Citric acid:**

Species : Rat  
NOAEL : 4,000 mg/kg  
LOAEL : 8,000 mg/kg  
Application Route : Ingestion  
Exposure time : 10 Days

**Sodium metabisulphite:**

Species : Rat  
NOAEL : 110 mg/kg  
LOAEL : 220 mg/kg  
Application Route : Ingestion  
Exposure time : 104 Weeks

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****levamisole hydrochloride:**

Ingestion : Symptoms: Nausea, Vomiting, Headache, Dizziness, hypotension



**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue:
8.0	17.06.2025	10808158-00009	14.04.2025
			Date of first issue: 05.07.2022

---

**Section 12: Ecological information****Ecotoxicity****Components:****levamisole hydrochloride:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 37.3 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 64 mg/l  
aquatic invertebrates : Exposure time: 48 h  
Method: OECD Test Guideline 202

**oxfendazole:**

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2.7 mg/l  
Exposure time: 96 h

LC50 (Oncorhynchus mykiss (rainbow trout)): > 2.5 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 0.059 mg/l  
aquatic invertebrates : Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic : EC50 (Pseudokirchneriella subcapitata (green algae)): > 4  
plants : mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): > 4  
mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox- : 10  
icity)

Toxicity to daphnia and other : NOEC (Daphnia magna (Water flea)): 0.023 mg/l  
aquatic invertebrates (Chron- : Exposure time: 21 d  
ic toxicity) : Method: OECD Test Guideline 211

M-Factor (Chronic aquatic : 1  
toxicity)

**Polyethylene glycol stearate:**

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 10,000 mg/l  
Exposure time: 96 h  
Method: DIN 38412

Toxicity to microorganisms : EC10 (Bacteria): > 10,000 mg/l

## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
8.0	17.06.2025	10808158-00009	14.04.2025
			Date of first issue: 05.07.2022

---

Exposure time: 16 h

**Citric acid:**Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l  
Exposure time: 96 hToxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 1,535 mg/l  
aquatic invertebrates Exposure time: 24 h**Sodium metabisulphite:**Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 178 mg/l  
Exposure time: 96 hToxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 89 mg/l  
aquatic invertebrates Exposure time: 48 hToxicity to algae/aquatic : ErC50 (Desmodesmus subspicatus (green algae)): 43.8 mg/l  
plants Exposure time: 72 hEC10 (Desmodesmus subspicatus (green algae)): 33.3 mg/l  
Exposure time: 72 hToxicity to fish (Chronic tox- : NOEC (Danio rerio (zebra fish)): >= 316 mg/l  
icity) Exposure time: 34 d  
Method: OECD Test Guideline 210  
Remarks: Based on data from similar materialsToxicity to daphnia and other : NOEC (Daphnia magna (Water flea)): >= 10 mg/l  
aquatic invertebrates (Chron- Exposure time: 21 d  
ic toxicity)Toxicity to microorganisms : EC10 (Pseudomonas putida): 30.8 mg/l  
Exposure time: 17 h**Persistence and degradability****Components:****oxfendazole:**

Stability in water : Hydrolysis: &lt; 5 % (4 d)

**Polyethylene glycol stearate:**Biodegradability : Result: Readily biodegradable.  
Biodegradation: > 70 %  
Exposure time: 10 d  
Method: OECD Test Guideline 302B**Citric acid:**Biodegradability : Result: Readily biodegradable.  
Biodegradation: 97 %

## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
8.0	17.06.2025	10808158-00009	Date of first issue: 05.07.2022

---

Exposure time: 28 d  
Method: OECD Test Guideline 301B

**Bioaccumulative potential****Components:****oxfendazole:**

Partition coefficient: n-octanol/water : log Pow: 1.95

**Citric acid:**

Partition coefficient: n-octanol/water : log Pow: -1.72

**Mobility in soil****Components:****oxfendazole:**

Distribution among environmental compartments : log Koc: 3.2

**Other adverse effects**

No data available

---

**Section 13: Disposal considerations****Disposal methods**

Waste from residues	: Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

**Section 14: Transport information****International Regulations****UNRTDG**

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxfendazole)
Class	: 9
Packing group	: III
Labels	: 9
Environmentally hazardous	: yes

**IATA-DGR**

UN/ID No.	: UN 3082
Proper shipping name	: Environmentally hazardous substance, liquid, n.o.s. (oxfendazole)

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
8.0	17.06.2025	10808158-00009	Date of first issue: 05.07.2022

---

Class : 9  
Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 964  
Packing instruction (passenger aircraft) : 964  
Environmentally hazardous : yes

**IMDG-Code**

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxfendazole)

Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations****NZS 5433**

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxfendazole)  
Class : 9  
Packing group : III  
Labels : 9  
Hazchem Code : 3Z  
Marine pollutant : no

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

---

**Section 15: Regulatory information****Safety, health and environmental regulations/legislation specific for the substance or mixture****HSNO Approval Number**

HSR100759 Veterinary Medicines Non dispersive Open System Application Group Standard

Tolerable Exposure Limits (TEL)

Not applicable

## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
8.0	17.06.2025	10808158-00009	Date of first issue: 05.07.2022

---

Environmental Exposure Limits (EEL)

Not applicable

**HSW Controls**

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

**The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

---

**Section 16: Other information**

Revision Date : 17.06.2025

**Further information**Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA : 8-hour, time-weighted average

NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Con-

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
8.0	17.06.2025	10808158-00009	Date of first issue: 05.07.2022

---

centration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN